Insmed INSM
Insmed is a biopharmaceutical company focused on developing and commercializing therapies for rare and serious diseases, with Arikayce as its main product for non-tuberculous mycobacterial lung infections. Insmed shows explosive revenue growth (296%) driven by Arikayce, but its profitability is deeply negative (operating margin -23.81%) and its valuation is demanding (forward P/E 153.71), reflecting a high-risk, high-reward profile.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Insmed is a biopharmaceutical company focused on developing and commercializing therapies for rare and serious diseases, with Arikayce as its main product for non-tuberculous mycobacterial lung infections. Insmed shows explosive revenue growth (296%) driven by Arikayce, but its profitability is deeply negative (operating margin -23.81%) and its valuation is demanding (forward P/E 153.71), reflecting a high-risk, high-reward profile.
Score by category
| Category | Score |
|---|---|
| Financial health | 5.9 |
| Quality / Moat | 3.3 |
| Valuation | 2.0 |
| Growth | 10.0 |
| Dividend | 1.5 |
| Momentum | 1.0 |
| Risk & Context | 6.8 |
OVERALL SCORE: 4.5/10
Context and risks
The biotech sector is under pressure from renewed concerns about AI safety, which is affecting technology and high-growth stocks. However, Insmed's primary risk is regulatory and competitive, not geopolitical.
News considered in the analysis
- Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients? — La revisión prioritaria de la FDA para la expansión de la etiqueta de Arikayce es un evento regulatorio material que amplía el mercado direccionable del fármaco principal.
- FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce — La aceptación de la solicitud por parte de la FDA es un hito regulatorio concreto que respalda el crecimiento futuro de los ingresos de Arikayce.
- Did FDA Priority Review of ARIKAYCE ENCORE Data Just Shift Insmed's (INSM) Investment Narrative? — El análisis de la narrativa de inversión refleja el impacto potencial de los datos de ENCORE, pero es una evaluación especulativa sobre el sentimiento del mercado.
- Can LQDA's Yutrepia Outpace Intensifying PAH Competition? — La mención de la creciente competencia en la hipertensión arterial pulmonar (HAP) es un riesgo para el segmento, pero no es específico de Insmed y su efecto es incierto.
- What BioPharma Credit (BPCP) Said on Its H1 Earnings Call — Titular no relacionado con Insmed; se refiere a un vehículo de inversión en regalías farmacéuticas.
Verdict: Hold; the label expansion for Arikayce is a clear catalyst, but the valuation already prices in a lot of optimism.
Main risk: The main risk is the dependence on a single drug (Arikayce) and increasing competition in the rare lung disease market, which could limit future growth potential.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →